Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings

Pediatric Pathology and Molecular Medicine

Volumn 18, Issue 6, 1998, Pages 471-481

  Matalon, Reuben ^a,c   Michals Matalon, Kimberlee ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Aspartoacylase; Canavan disease; Macrocephaly; N acetylaspartic acid; Review; Spongy degeneration of the brain

Indexed keywords

ACETAZOLAMIDE; ACETIC ACID; AMIDASE; AMINO ACID; ASPARTIC ACID; COMPLEMENTARY DNA; DNA; N ACETYLASPARTIC ACID;

ARTICLE; BRAIN BIOPSY; CANAVAN DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ENZYME DEFICIENCY; GASTROSTOMY; GENE MUTATION; GENE THERAPY; HETEROZYGOTE; HUMAN; JEW; NONHUMAN; NOSE FEEDING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL;

EID: 84867105643     PISSN: 15227952     EISSN: None     Source Type: Journal    
DOI: 10.1080/152279598405625     Document Type: Article

References (49)

1. Canavan MM. Schilder's encephalitis periaxialis diffusa. Arch Neurol Psychiatr 1931;25:299-308.
2. Globus JH, Strauss I. Progressive degenerative subcortical encephalopathy (Schilder's disease). Arch Neurol Psychiatr 1928;20:1190-1228.
3. van Bogaert L, Bertrand I. Sur une idiote familiale avec degenerescence spongieuse de neuraxe (note preliminaire). Acta Neurol Belg 1949;12:572-587.
4. Banker BQ, Victor H. Spongy degeneration of infancy. In: Genetic Diseases Among Ashkenazijews. Eds: Goodman, Motulsky Raven Press, NY 1979.
5. Matalon R, Michals K, Sebasta D, Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988;29:463-471.
6. Kaul RK, Gao GP, Balamurugan K, Matalon R. Human aspartoacylase cDNA and mis-sense mutation in Canavan disease. Nature Genetics 1993;5:118-123.
7. Matalon R, Kaul R, Michals K. Canavan disease. In: The Molecular and Genetic Basis of Neurological Disease Eds: Rosenberg R, Prusiner S, DiMauro S, Barchi R, Butterworth-Heinemann, Boston 1997.
8. Tallan HH, Moore S, Stein WH. N-Acetyl-L-aspartic acid in brain. J Biol Chem 1956;219:257-264.
9. McIntosh JM, Cooper JR. Studies on the function of N-acetylaspartic acid in the brain. J Neurochem. 1965;12:825.
10. Ory-Lavolle L, Blakely RD, Coyle JT. Neurochemical and immunochemical studies on the distribution of N-acetylaspartylglutamate and N-acetyl-aspartate in rat spinal cord and some peripheral nervous tissues. J Neurochem 1987;48:895-899.
11. Kaul R, Michals K, Casanova J, Matalon R. The role of N-acetylaspartic acid in brain metabolism and the pathogenesis in Canavan disease. Intl Pediatrics 1991;6:0-43.
12. Baslow MH. Molecular water pumps and the aetiology of Canavan disease: A case of the sorcerer's apprentice. J Inher Metab Dis. 1999;99-101.
13. Adachi M, Torii J, Schneck L, Volk BW: Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration (van Bogaert and Bertrand type). Acta Neuropath 1972;20:22-31.
14. Adornato BT, O'Brien JS, Lampert PW, Roe TF, Neustein HB. Cerebral spongy degeneration of infancy: a biochemical and ultrastructural study of affected twins. Neurology 1972;22:202-210.
15. Matalon R, Matalon-Michals K. Recent Advances in Canavan disease. Advances in Pediatr 1999;46:493-506.
16. Luo Y, Huang K. Spongy degeneration of the CNS in infancy. Arch Neurol 1984;41:164-170.
17. Rushton AR, Shaywitz BA, Dumen CC, Geehr RB, Maneulidis EE. Computerized tomography in the diagnosis of Canavan's disease. Ann Neurol 1981;10:57-60.
18. Brismar J, Brismar G, Gascon G, Ozand P. Canavan disease: CT and MR imaging of the brain. Am J Neurol Res 1990;11:805-810.
19. Matalon R, Michals K, Kaul R, Mafee M. Spongy degeneration of the brain, Canavan disease. Int Pediatr 1990;5:121-124.
20. Grodd W, Krageloh-Mann I, Peterson D, Trcfz FK, Harzer K. In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan disease) by proton spectroscopy Lancet 1990;336:437-438.
21. Wittsack HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized IH MR spectroscopy in children with Canavan's disease J Magn Reson Imaging 1996;6:889-893.
22. Topcu M, Erde G, Saatci I, Aktan G, Simsek A, Renda Y, Schutgens RB, Wanders RJ, Jacobs C. Clinical and Magnetic Resonance Imaging Features of L-2-Hydroxyglutaric Acidemia: Report of Three Cases in Comparison to Canavan Disease. J Child Neurol 1996;373-377.
23. Goutieres F, Boullouche JJ, Bourgeois M, Aicardi J. Leukoencephalopathy, megalencephaly, and mild clinical course. A recently individualized familial leukodystrophy. Report on five new cases. J Child Neuro 1996;11:439-444.
24. van der Knapp MS, Barth PG, Vrensen GF, Valk J. Histopathology of an infantile-onset spongiform leukoencephalopathy with a discrepantly mild clinical course. Acta Neuropathol 1996;92:206-212.
25. Mejaski-Bosnjak V, Besenski N, Brockmann K, Pouwels PJ, Frahm J, Hanefeld FA. Cystic leukoencephalopathy in a megalencephalic child: Clinical and magnetic resonance imaging/magnetic resonance spectroscopy findings. Pediatr. Neurol. 1997;16:347-350.
26. Chou SM, Waisman HA. Spongy degeneration of the central nervous system, case of homocystinuria. Arch Pathol 1965;70:357-363.
27. Rushton DI. Spongy degeneration of the white matter of the central nervous system associated with hyperglycinuria J Clin Pathol 1966;21:456-462.
28. Lisson G, Leupold DD, Bechinger C, Wallesch: CT findings in a case of deficiency of 3-hydroxy-3methylglutaryl CoA lyase. Neuroradiology 1981;22:99-101.
29. Walters GF. Molecular pathological aspects in spongy encephalopathies. Wien Klin Wochenschr 1982;94:375-376.
30. Egger J, Wayne-Williams CJ, Erdohazi M. Mitochondrial cytopathy or Leigh's syndrome? Mitochondrial abnormalities in spongiform encephalopathies. Neuropediatrics 1992;13:219-224.
31. Matalon R, Kaul R, Casanova J, Michals K, Johnson A, Rapin I, Gashkoff P. Deanching M. Aspartoacylase deficiency: the enzyme defect in Canavan disease J Inner Metab Dis 1989;12:463-471.
32. Kaul RK, Balamurugan K, Gao GP, Matalon R: Canavan disease: Genomic organization and localization of human ASPA gene during evolution Genomics 1994;21:364-370.
33. Kaul R, Gao GP, Aloya M, Balamurugan K, Petrosky A, Michals K, Matalon R. Canavan disease: Mutations among Jewish and non-Jewish patients. Am J Hum Genet 1994;55:34-41.
34. Matalon R, Kaul R, Michals. Carrier rate of Canavan disease among Ashkenazi Jewish individuals. Am J Hum Genet 1994;55:A908.
35. Kronn D, Oddoux C, Phillips J, Ostrer H. Prevalence of Canavan disease heteroxygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet 1995;57:1250-1252.
36. Kaul R, Gao GP, Matalon R, Aloya M, Su Q, Jin M, Johnson AB, Schutgens RB, Clarke JT. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am J Hum Genet 1996;59:95-102.
37. Shaag A, Anikster Y, Christensen E, Glustein JZ, Fois A, Michelakakis H, Nigro F, Pronicka E, Ribes A, Zabot MT, Elpeleg ON. The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet 1995;57:572-80.
38. Kaul R, Gao GP, Michals K, Whelan DT, Levin S, Matalon R. A novel (cys152 > arg) missense mutation in Arab patient with Canavan disease. Hum Mutat 1995;5:269-271.
39. Kobayashi K, Tsujino S, Ezoe T, Hamaguchi H, Nihei K, Sakuragawa N. A missense mutation (I143T) in a Japanese patient with Canavan disease. Hum Mutat 1998;S308-S309.
40. Elpeleg ON, Shaag A. The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients J Inner Metab Dis 1999;22:531-534.
41. Rady PL, Penzien JM, Vargas T, Tyring SK, Matalon R. Novel Splice Site Mutation of Aspartoacylase gene in a Turkish patient with Canavan disease. Euro J Pediatr Neurol. In press.
42. Rady PL, Vargas T, Tyring SK, Matalon R, Langenbeck U. Novel Missense (Y231C) in a Turkish patient with Canavan disease. Am J Med Gene. In press.
43. During M. Gene Therapy in New Zealand. Science 1996;272:467.
44. Bluml S, Seymour K, Philippart M. Matalon R, Ross R. Elevated brain water in Canavan disease: Impact of a diuretic therapy. Intl Soc Magn Res 1998;171.
45. Matalon R, Matalon-Michals K. Prenatal diagnosis of Canavan disease. Prenatal Diagnosis 1999;7:669-670.
46. Matalon R, Kaul R, Gao GP, Michals K, Gray RG, Bennet-Briton S, Norman A, Smith M, Jakobs C. Prenatal diagnosis for Canavan disease: The use of DNA markers. J Inner Metab Dis 1995;18:215-217.
47. Bennett MJ, Gibson KM, Sherwood WG, Divry P, Rolland MO, Elpeleg ON, Rinaldo P, Jacobs C. Reliable prenatal diagnosis of Canavan disease (Aspartoacylase deficiency): Comparison of enzymatic and metabolite analysis J Inher Metab Dis 1993;16:831-836.
48. Kelley RI. Prenatal diagnosis of Canavan disease by measurement of N-acetyl-L-aspartate in amniotic fluid. J Inher Metab Dis 1993;16:918-919.
49. Matalon R, Rady P, Platt K, Skinner HB, Quast MJ, Campbell GA, Matalon K, Ceci JD, Jyring SK, Nehls M, Wei J, Szucs S. Knock-out mouse for Canavan disease: A model for gene transfer to the central nervous system. J Gene Med, 2000. In press.